(JXN) Jackson Financial - Overview
Stock: Annuity, Investment Contract, Life Insurance, Investment Management
| Risk 5d forecast | |
|---|---|
| Volatility | 43.7% |
| Relative Tail Risk | -3.98% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.91 |
| Alpha | 5.71 |
| Character TTM | |
|---|---|
| Beta | 1.562 |
| Beta Downside | 2.282 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.09% |
| CAGR/Max DD | 1.27 |
EPS (Earnings per Share)
Revenue
Description: JXN Jackson Financial March 02, 2026
Jackson Financial Inc. (NYSE:JXN) offers a diversified suite of annuity and insurance products through three core segments: Retail Annuities, Institutional Products, and Closed Life & Annuity Blocks. The Retail segment delivers variable, fixed-index, fixed, and payout annuities plus lifetime income solutions, while Institutional provides guaranteed investment contracts and funding-agreement notes tied to the Federal Home Loan Bank program. The Closed Life segment sells whole-life, universal, and term life policies along with group payout annuities and investment-management services, reaching customers via brokers, banks, RIAs, and insurance agents.
In its most recent fiscal quarter (Q3 2025), Jackson reported revenue of $312 million, a 6% year-over-year increase, and net income of $28 million, translating to an EPS of $0.84. The company’s return on equity rose to 12.4% and it maintained a dividend yield of roughly 2.3%, reflecting steady cash-flow generation from its fee-based annuity platform.
Key drivers for Jackson’s outlook include the aging U.S. population, which fuels demand for retirement income products, and the recent upward shift in interest rates that enhances the spread on fixed-index annuities. Additionally, regulatory clarity around variable annuity disclosures is expected to support continued growth in the Retail segment.
For a deeper dive into valuation metrics, check out ValueRay.
Headlines to watch out for
- Annuity sales growth impacts revenue and profitability
- Interest rate fluctuations affect investment income
- Regulatory changes could increase compliance costs
- Market volatility influences investment portfolio performance
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 27.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.75 > 1.0 |
| NWC/Revenue: -138.5% < 20% (prev 1593 %; Δ -1732 % < -1%) |
| CFO/TA 0.02 > 3% & CFO 5.76b > Net Income 27.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (70.3m) vs 12m ago -5.57% < -2% |
| Gross Margin: 85.47% > 18% (prev 0.77%; Δ 8470 % > 0.5%) |
| Asset Turnover: 1.96% > 50% (prev 0.91%; Δ 1.04% > 0%) |
| Interest Coverage Ratio: 0.08 > 6 (EBITDA TTM -14.0m / Interest Expense TTM 100.0m) |
Altman Z'' -0.09
| A: -0.03 (Total Current Assets 5.70b - Total Current Liabilities 14.96b) / Total Assets 344.53b |
| B: 0.02 (Retained Earnings 7.47b / Total Assets 344.53b) |
| C: 0.00 (EBIT TTM 8.00m / Avg Total Assets 341.49b) |
| D: 0.01 (Book Value of Equity 5.00b / Total Liabilities 334.19b) |
| Altman-Z'' Score: -0.09 = B |
Beneish M
| DSRI: 0.41 (Receivables 19.64b/21.95b, Revenue 6.68b/3.09b) |
| GMI: 0.90 (GM 85.47% / 77.30%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 2.16 (Revenue 6.68b / 3.09b) |
| TATA: -0.02 (NI 27.0m - CFO 5.76b) / TA 344.53b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of JXN shares?
Over the past week, the price has changed by -2.12%, over one month by -7.99%, over three months by +11.03% and over the past year by +39.71%.
Is JXN a buy, sell or hold?
- StrongBuy: 0
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the JXN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 125.3 | 14.5% |
| Analysts Target Price | 125.3 | 14.5% |
JXN Fundamental Data Overview March 07, 2026
P/B = 0.8616
Revenue TTM = 6.68b USD
EBIT TTM = 8.00m USD
EBITDA TTM = -14.0m USD
Long Term Debt = 2.03b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 2.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.67b USD (from netDebt column, last quarter)
Enterprise Value = 4.21b USD (7.88b + Debt 2.03b - CCE 5.70b)
Interest Coverage Ratio = 0.08 (Ebit TTM 8.00m / Interest Expense TTM 100.0m)
EV/FCF = 0.50x (Enterprise Value 4.21b / FCF TTM 8.50b)
FCF Yield = 202.0% (FCF TTM 8.50b / Enterprise Value 4.21b)
FCF Margin = 127.2% (FCF TTM 8.50b / Revenue TTM 6.68b)
Net Margin = 0.40% (Net Income TTM 27.0m / Revenue TTM 6.68b)
Gross Margin = 85.47% ((Revenue TTM 6.68b - Cost of Revenue TTM 971.0m) / Revenue TTM)
Gross Margin QoQ = none% (prev 27.58%)
Tobins Q-Ratio = 0.01 (Enterprise Value 4.21b / Total Assets 344.53b)
Interest Expense / Debt = 1.23% (Interest Expense 25.0m / Debt 2.03b)
Taxrate = 21.0% (US default 21%)
NOPAT = 6.32m (EBIT 8.00m * (1 - 21.00%))
Current Ratio = 0.38 (Total Current Assets 5.70b / Total Current Liabilities 14.96b)
Debt / Equity = 0.20 (Debt 2.03b / totalStockholderEquity, last quarter 9.95b)
Debt / EBITDA = 262.4 (negative EBITDA) (Net Debt -3.67b / EBITDA -14.0m)
Debt / FCF = -0.43 (Net Debt -3.67b / FCF TTM 8.50b)
Total Stockholder Equity = 10.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.01% (Net Income 27.0m / Total Assets 344.53b)
RoE = 0.26% (Net Income TTM 27.0m / Total Stockholder Equity 10.21b)
RoCE = 0.07% (EBIT 8.00m / Capital Employed (Equity 10.21b + L.T.Debt 2.03b))
RoIC = 0.04% (NOPAT 6.32m / Invested Capital 14.24b)
WACC = 9.48% (E(7.88b)/V(9.91b) * Re(11.67%) + D(2.03b)/V(9.91b) * Rd(1.23%) * (1-Tc(0.21)))
Discount Rate = 11.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -6.23%
[DCF] Terminal Value 73.21% ; FCFF base≈7.42b ; Y1≈7.57b ; Y5≈8.34b
[DCF] Fair Price = 1655 (EV 113.28b - Net Debt -3.67b = Equity 116.96b / Shares 70.7m; r=9.48% [WACC]; 5y FCF grow 1.85% → 2.90% )
EPS Correlation: 59.35 | EPS CAGR: 14.79% | SUE: 0.85 | # QB: 1
Revenue Correlation: 3.44 | Revenue CAGR: -1.42% | SUE: -0.38 | # QB: 0
EPS next Quarter (2026-06-30): EPS=5.89 | Chg7d=+0.100 | Chg30d=+0.100 | Revisions Net=+2 | Analysts=2
EPS current Year (2026-12-31): EPS=23.95 | Chg7d=-0.290 | Chg30d=-0.290 | Revisions Net=+2 | Growth EPS=+5.6% | Growth Revenue=+17.5%
EPS next Year (2027-12-31): EPS=26.97 | Chg7d=+0.398 | Chg30d=+0.398 | Revisions Net=+1 | Growth EPS=+12.6% | Growth Revenue=+3.4%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)